Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Buy
52
CI Quote, Financials, Valuation and Earnings
Last price:
$316.61
Seasonality move
:
1.51%
Day range:
$310.05 - $319.25
52-week range:
$262.03 - $370.83
Dividend yield:
1.8%
P/E ratio:
17.53x
P/S ratio:
0.35x
P/B ratio:
2.10x
Volume:
2.7M
Avg. volume:
1.8M
1-year change:
-4.34%
Market cap:
$84.6B
Revenue:
$244.4B
EPS (TTM):
$18.06
Analysts' Opinion
-
Consensus RatingThe Cigna Group has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $375.21, The Cigna Group has an estimated upside of 18.5% from its current price of $316.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $330.60 representing 100% downside risk from its current price of $316.64.
Fair Value
-
According to the consensus of 18 analysts, The Cigna Group has 18.5% upside to fair value with a price target of $375.21 per share.
CI vs. S&P 500
-
Over the past 5 trading days, The Cigna Group has underperformed the S&P 500 by -0.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
The Cigna Group does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Cigna Group has grown year-over-year revenues for 61 quarters straight. In the most recent quarter The Cigna Group reported revenues of $65.5B.
Earnings Growth
-
The Cigna Group has grown year-over-year earnings for 1 quarter straight. In the most recent quarter The Cigna Group reported earnings per share of $4.85.
Enterprise value:
106.2B
EV / Invested capital:
--
Price / LTM sales:
0.35x
EV / EBIT:
12.77x
EV / Revenue:
0.42x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
17.66x
Price / Operating cash flow:
14.67x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
3.26%
Net Income Margin (TTM):
1.98%
Return On Equity:
12.17%
Return On Invested Capital:
6.86%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $182.8B | $204.1B | $254.5B | $55.4B | $65.5B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $21.93 | $12.18 | $18.06 | -$0.97 | $4.85 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.7B | $26.1B | $31.8B | $34.8B | $40.4B | |
| Total Assets | $152.1B | $152.6B | $148B | $153.1B | $150.7B | |
| Current Liabilities | $27.7B | $31.9B | $37.6B | $43B | $49.8B | |
| Total Liabilities | $103.9B | $106.4B | $103.4B | $111.8B | $110.2B | |
| Total Equity | $48.2B | $46.2B | $44.6B | $41.4B | $40.4B | |
| Total Debt | $32B | $33.2B | $32.5B | $32.8B | $30.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.7B | $11.6B | $7.4B | $4.8B | $1.9B | |
| Cash From Investing | $439M | -$2.7B | -$410M | -$495M | $1.2B | |
| Cash From Financing | -$9.1B | -$6.8B | -$8.8B | -$2.5B | -$3.7B | |
| Free Cash Flow | $10.2B | $10.2B | $6B | $4.5B | $1.6B | |
CI
Sector
Market Cap
$84.6B
$33.4M
Price % of 52-Week High
85.39%
45.25%
Dividend Yield
1.8%
0%
Shareholder Yield
6.72%
-0.66%
1-Year Price Total Return
-4.34%
-40%
Beta (5-Year)
0.472
0.653
Dividend yield:
1.8%
Annualized payout:
$5.60
Payout ratio:
31.35%
Growth streak:
4 years
Technicals
8-day SMA
Buy
Level
$315.70
200-day SMA
Sell
Level
$320.77
Bollinger Bands (100)
Buy
Level
293.32 - 328.96
Chaikin Money Flow
Buy
Level
164.3M
20-day SMA
Sell
Level
$320.05
Relative Strength Index (RSI14)
Sell
Level
46.64
ADX Line
Sell
Level
20.62
Williams %R
Neutral
Level
-36.3025
50-day SMA
Sell
Level
$324.82
MACD (12, 26)
Sell
Level
-3.53
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
288.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4082)
Sell
CA Score
(Annual)
Level (-0.6445)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.3121)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.
Stock Forecast FAQ
In the current month, CI has received 12 Buy ratings 6 Hold ratings, and 0 Sell ratings. The CI average analyst price target in the past 3 months is $375.21.
-
Where Will The Cigna Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Cigna Group share price will rise to $375.21 per share over the next 12 months.
-
What Do Analysts Say About The Cigna Group?
Analysts are divided on their view about The Cigna Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Cigna Group is a Sell and believe this share price will drop from its current level to $330.60.
-
What Is The Cigna Group's Price Target?
The price target for The Cigna Group over the next 1-year time period is forecast to be $375.21 according to 18 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is CI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Cigna Group is a Buy. 12 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CI?
You can purchase shares of The Cigna Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Cigna Group shares.
-
What Is The The Cigna Group Share Price Today?
The Cigna Group was last trading at $316.61 per share. This represents the most recent stock quote for The Cigna Group. Yesterday, The Cigna Group closed at $316.64 per share.
-
How To Buy The Cigna Group Stock Online?
In order to purchase The Cigna Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
